Agilent Technologies Inc (NYSE:A) was the recipient of unusually large options trading on Tuesday. Investors acquired 3,802 put options on the company. This is an increase of approximately 2,218% compared to the average volume of 164 put options.
In other news, CEO Michael R. Mcmullen sold 17,491 shares of the company’s stock in a transaction on Wednesday, January 30th. The stock was sold at an average price of $75.00, for a total value of $1,311,825.00. Following the sale, the chief executive officer now directly owns 456,430 shares in the company, valued at $34,232,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Mark Doak sold 16,421 shares of the company’s stock in a transaction on Friday, February 22nd. The shares were sold at an average price of $77.95, for a total value of $1,280,016.95. The disclosure for this sale can be found here. Insiders have sold 83,722 shares of company stock worth $6,532,504 in the last ninety days.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc lifted its holdings in Agilent Technologies by 0.8% during the 3rd quarter. Vanguard Group Inc now owns 24,155,483 shares of the medical research company’s stock worth $1,703,929,000 after buying an additional 194,607 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Agilent Technologies by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,234,035 shares of the medical research company’s stock worth $285,139,000 after buying an additional 285,330 shares during the last quarter. Northern Trust Corp lifted its holdings in Agilent Technologies by 2.0% during the 4th quarter. Northern Trust Corp now owns 3,807,998 shares of the medical research company’s stock worth $256,888,000 after buying an additional 75,416 shares during the last quarter. Findlay Park Partners LLP bought a new position in Agilent Technologies during the 4th quarter worth approximately $246,229,000. Finally, Cantillon Capital Management LLC lifted its holdings in shares of Agilent Technologies by 0.7% in the 4th quarter. Cantillon Capital Management LLC now owns 3,557,589 shares of the medical research company’s stock worth $239,994,000 after purchasing an additional 24,411 shares during the last quarter.
Shares of NYSE A opened at $77.55 on Wednesday. Agilent Technologies has a fifty-two week low of $60.42 and a fifty-two week high of $82.27. The company has a quick ratio of 2.79, a current ratio of 3.39 and a debt-to-equity ratio of 0.36. The company has a market cap of $25.53 billion, a price-to-earnings ratio of 27.80, a price-to-earnings-growth ratio of 2.23 and a beta of 1.38.
Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, February 20th. The medical research company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.03. Agilent Technologies had a return on equity of 19.90% and a net margin of 22.86%. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same quarter last year, the firm earned $0.66 EPS. Agilent Technologies’s quarterly revenue was up 6.0% on a year-over-year basis. Equities analysts expect that Agilent Technologies will post 3.06 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd will be paid a dividend of $0.164 per share. The ex-dividend date of this dividend is Monday, April 1st. This represents a $0.66 dividend on an annualized basis and a yield of 0.85%. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.66%.
ILLEGAL ACTIVITY WARNING: “Agilent Technologies Target of Unusually Large Options Trading (A)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://sportsperspectives.com/2019/04/17/agilent-technologies-target-of-unusually-large-options-trading-a.html.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Further Reading: The Discount Rate – What You Need to Know
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.